Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

WCLC 2024

7 - 10 Sep 2024

Published: 26 Sep 2024

Views: 442

Rating:

Save

Dr Marina Garassino - University of Chicago, Chicago, USA

Dr Marina Garassino speaks to ecancer about the longer follow-up of the MARIPOSA study. The updated analysis compared the effectiveness of the combination of amivantamab and lazertinib with osimertinib.

The study results indicated that amivantamab and lazertinib continue to demonstrate a trend towards improved overall survival and better post-progression outcomes compared to osimertinib.

This reaffirms that amivantamab-lazertinib is a first-line standard-of-care treatment for EGFR-mutated advanced NSCLC.

Related Videos

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer

Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer ( Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA )

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

More from ecancer